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Abstract 
Suppression of Cytokine Signalling-3 (SOCS-3) modulates 
the inflammatory pathways responsible for vascular 
stability. Therefore, we aimed to estimate SOCS-3 levels in 
2nd trimester pregnant females and correlate it with 
blood pressure. A case control study recruiting (n=111) 
females was conducted at the Aga Khan University. They 
were classified as pregnancy induced hypertensives or 
normotensive as per American College of Obstetricians 
and Gynecologists Guidelines. Weight, Body mass index, 
lipid profile and blood glucose were recorded while 
SOCS-3 was measured by ELISA. Higher SOCS-3 levels 
were seen in hypertensive group (30 pg/ml) versus 
normotensive (16 pg/ml).  Both Systolic & diastolic blood 
pressure (r=0.520; p<0.001) (r=0.490; p<0.001) showed an 
independent significant positive correlation with SOCS-3 
level. It is safe to suggest that SOCS-3 has an association 
of causing high blood pressure. However, more research 
needs to be conducted to establish a mechanism and 
chronological order to these events in a pregnant female. 
Keywords: Hypertension, Pregnancy, SOCS-3, Obesity. 
Introduction 
Pregnancy induced hypertension (PIH) is the 
development of new hypertension in a pregnant woman 
20 weeks after gestation without the presence of protein 
in the urine or other signs of preeclampsia.PIH 
complicates around 6-10% of all pregnancies around the 
world.1 These complications include pre-eclampsia, 
nervous system dysfunction, pulmonary oedema, 
elevated liver enzymes during pregnancy in the mother2 
and for the foetus, it may lead to intrauterine growth 
restriction (IUGR), premature birth or even death in 
extreme conditions.1 In Pakistan itself, the morbidity and 
mortality are significantly higher — of 100 cases admitted 
for PIH, complications were seen in 98, one of them 
resulting in death due to inadequate antenatal 
management.3,4 
The underlying cause of gestational hypertension in 
humans is commonly believed to be an improperly 
implanted placenta, or abnormal levels of inflammatory 
cytokines. The hypothesised mechanism by which PIH 
occurs is that the pro inflammatory state seen in 
pregnancy can lead to vascular damage and 
hypertension. This can be accounted by multiple possible 
factors, such as a low anti-oxidant/oxidant ratio, which 
would suggest that reactive oxygen species are able to 
cause more damage to the blood vessels in the pregnant 
females.1 Some cases have been seen where there is 
increased natural killer cell function (due to increased 
production of stimulatory cytokines) which is the 
potential cause for the damage that leads to the 
development of high blood pressure.5 
One such protein is called the Suppression of Cytokine 
Signaling (SOCS) which has a family of eight members 
(SOCS1-7 and CIS). These are modulators of the 
inflammatory pathway, that act by inhibiting the 
activation of Janus kinase-signal transducer and is 
activator of transcription (JAK-STAT) pathway to transmit 
their information into the cell nucleus. This is achieved by 
three potential routes (a) inhibiting JAK proteins that 
have been activated directly, (b) being a competitive 
antagonist for STAT proteins, and (c) up regulating the 
proteasome lists of the STAT complexes. In this way, SOCS 
is said to be involved in the regulation of the 
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inflammatory mediators, controlling the degree of the 
adverse effect.6 Lately, additional roles are identified in 
suppressing the inflammatory pathways in the immune 
system and in cancer biology.7 Yet, the functional 
importance of SOCS-3 in regulating vascular health is 
largely unknown but may be taken as an upcoming 
marker for metabolic diseases8 (Figure-1A). Therefore, we 
aimed to estimate SOCS-3 levels in 2nd trimester 
pregnant females and correlate the levels with blood 
pressure. 
Subjects and Methods 
A case control study was conducted at the Aga Khan 
University, Karachi from January 2017 till February 2018.  
Inclusion criteria included pregnant females in their 2nd 
trimester (13 to 27 weeks) between the ages of 20-35 years. 
While females with any comorbid such as gestational 
diabetes, twin pregnancies, chronic cardio metabolic illness 
or infectious diseases such as HIV, HBV, HCV or females on 
anti-inflammatory medication, were excluded from the 
study. Furthermore, females with pre-existing hypertension, 
and complicated cases were excluded from this study. The 
sample size was calculated using the Open-Epi website,9 
with 1:1 distribution of cases and controls, where 
confidence level of 95%, power of 80%, least extreme odds 
ratio (OR) of 2 and a pregnancy hypertension prevalence of 
8% was chosen as this was the result according to 
previously published data sources.10 The minimum sample 
size calculated for this research was 106.More than 150 
pregnant ladies were contacted from the outpatient clinics 
and community health centre waiting room areas, and a 
total of 111 females agreed to participate and were 
recruited for this study. All the study participants gave a 
written and informed consent to participate in the study. 
Weight, height, BMI at the time of admittance, gestational 
age, family history lipid, profile and blood glucose level were 
recorded for all subjects. A blood pressure measurement 
was performed on each subject and previous two blood 
pressure readings were recorded from the subject's file. The 
subjects were then classified for having pregnancy induced 
hypertension (PIH) following the ACOG Guideline which 
states that "A blood pressure of >140/90 mm Hg is 
considered as PIH (n=50),11 and normotensive (n= 61) by 
the convienient randomn technique. Written informed 
consent was obtained from the participants and five 
milliliters blood sample was collected after an overnight 
fast. Serum was separated and stored for comparative 
analysis. ELISA assays were used to detect SOCS-3 levels (kit 
cat # H1415 by Glorybioscince, Belgium). The study was 




Data was analysed by using SPSS version 23. Quantitative 
variables were expressed as mean ± standard deviation. 
The Mann Whitney U test was used to compare the level 
of SOCS-3 between pregnant females, with and without 
hypertension and chi square or Fischer extact test is 
applied wherever applicable. The Spearman ranks 
correlation was applied to test the association of SOCS-3 
with hypertension and obesity. In all instances, a p value 
of <0.05 was considered significant. 
Results and Conclusion 
The mean age and parity of the study subjects was on an 
average, matched between the two groups (p>0.05). 
Furthermore, obesity and lipid derangement are 
confounding factors for hypertension, SOCS-3 is 
associated with inhibiting insulin signaling which in turn 
inhibits the lipid reabsorption into the adipose tissue and 
liver.12 Therefore, in this study, we wanted to assess if 
there was any lipid derangement along with the 
disruption of SOCs-3 in the study subjects. No difference 
in the lipid profile levels was observed, suggesting that 
SOCs-3 may act as an independent marker for blood 
pressure in pregnancy. However, hypertensive pregnant 
females were obese and had a higher BMI compared to 
normotensive females (p<0.05). Higher SOCS-3 levels 
were seen in hypertensive group (30 pg/ml) versus 
normotensive (16 pg/ml) (Table). When we stratified ours 
groups based on BMI in order to assess the difference in 
SOCS-3 levels; higher levels were observed in 
hypertensive group across all BMI categories (Table-1). 
Lastly, we plotted a relationship curve between the 
biomarker, BMI and blood pressure. Both Systolic blood 
pressure (r=0.520; p<0.001) and diastolic blood pressure 
(r=0.490; p<0.001) showed a significant positive 
correlation with SOCS-3 level, whereas a non-significant 
association was observed with BMI (r=0.351; p=0.101) 
(Figure). The results of this study indicate that there is a 
positive correlation between SOCS-3 and hypertension. 
This signifies that SOCS-3 may play a role in the 
pathogenesis of the disease, and hence opening a 
possible area of research and treatment route for PIH. 
Previous studies have shown that a low level of SOCS-3 
was related to disease processes such as inhibition of 
differentiation of epithelial to mesenchymal cells and 
cellular proliferation in kidney proximal tubule cells.13 
However, our results show a higher SOCS-3 level in 
hypertensive individuals, suggests the possibility that 
SOCS-3 is being produced as a result of the inflammatory 
environment during pregnancy and obesity in an attempt 
to limit the inflammatory damage and maybe prevent the 
catastrophic effects of hypertension. We cannot comment 
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Table: Parameters of study subjects. 
 
Variable                                                                                                                                            Normotensive                                                        Hypertensive                                                           p value 
                                                                                                                                                                     (n= 61)                                                                      (n= 50) 
 
Age (year)                                                                                                                                               26.59 ± 5.26                                                              27.21± 5.93                                                                0.602 
Weight (kg)                                                                                                                                           65.52 ± 13.40                                                           72.37 ± 16.11                                                               0.032 
BMI (kg/m2)                                                                                                                                           25.69 ± 4.94                                                            27.95 ± 5.79*                                                               0.050 
Gestational Age (weeks)                                                                                                                    26.22 ± 2.15                                                             27.17 ± 1.24                                                                0.848 
Parity                                                                         Primi                                                                       40 (65.57)                                                                   33 (66.0)                                                                    0.648 
                                                                                    Multi                                                                       21 (34.42)                                                                    17 (34.0)                                                                          
Previous mode of delivery                                   LSCS                                                                          5 (8.19)                                                                        3 (6.00)                                                                     0.843 
                                                                                     SVD                                                                        56 (91.80)                                                                    47 (94.0)                                                                          
FBG (mg/dl)                                                                                                                                          93.32 ± 26.02                                                           91.53 ± 19.56                                                               0.733 
TAG (mg/dl)                                                                                                                                         144.32 ± 58.25                                                         147.62 ± 60.04                                                             0.798 
HDL (mg/dl)                                                                                                                                          50.96 ± 8.613                                                            51.65 ± 6.98                                                                0.698 
SBP (mmHg)                                                                                                                                        110.98 ± 10.44                                                        148.75 ±16.60*                                                           <0.001 
DBP (mmHg)                                                                                                                                          70.00 ± 8.63                                                          101.25 ±10.99*                                                           <0.001 
SOCs3 (pg/ml)                                                                                                                                      16.75 ± 7.402                                                         30.43 ± 13.505*                                                          <0.001 
 
Stratification of subjects based on Hypertension and BMI category 
 
Variable                      Normal Weight HTN         Overweight HTN          Obese HTN        Normal Weight  Normotensive      Overweight Normotensive     Obese  Normotensive 
                                                      (n=20)                                  (n=12)                        (n=18)                                     (n=21)                                                     (n=10)                                          (n=30) 
 
SOCS-3 (pg/ml)                     24.46 ±3.48                        37.34 ± 2.39               26.50 ±2.91                            12.61±  6.53                                            14.25 ±4.65                                 20.49 ±6.93 
 
Where: BMI (Body mass index), FBG (fasting blood glucose), TAG (triglyceride), HDL (high density lipoprotein), SBP (systolic blood pressure) DBP (diastolic blood pressure). Values expressed as Mean ± SD or 
absolute number with percentage in parenthesis. Groups compared by.
Figure-: Correlation of SOCS-3 with 
blood pressure and BMI.
on the role of SOC-3 an anti inflammtory marker as we 
were limited to measuring cytokine levels in the study 
subjects due to budget constraints. Yet more 
observations and information about SOCS-3 as a chemical 
(as to the exact effects in the body, the production and 
the potential side effects it's administration may have) 
would be required before considering this route. It is 
important to note that only a few studies were available 
on SOCS-3, obesity,14 diabetes and inflammatory 
cytokines.15 However, no articles were available that 
established associated levels of SOCS-3 with obesity or 
hypertension in pregnant females. Once a relationship 
between the two is established, levels of SOCS-3 can be 
monitored and changed through intervention to avoid 
comorbids like hypertension and other associated 
complications. 
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